GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ESSA Pharma Inc (NAS:EPIX) » Definitions » Shiller PE Ratio

EPIX (ESSA Pharma) Shiller PE Ratio : (As of Mar. 29, 2025)


View and export this data going back to 2015. Start your Free Trial

What is ESSA Pharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


ESSA Pharma Shiller PE Ratio Historical Data

The historical data trend for ESSA Pharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ESSA Pharma Shiller PE Ratio Chart

ESSA Pharma Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ESSA Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ESSA Pharma's Shiller PE Ratio

For the Biotechnology subindustry, ESSA Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ESSA Pharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ESSA Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where ESSA Pharma's Shiller PE Ratio falls into.


;
;

ESSA Pharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

ESSA Pharma's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, ESSA Pharma's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.19/127.3637*127.3637
=-0.190

Current CPI (Dec. 2024) = 127.3637.

ESSA Pharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -4.000 99.789 -5.105
201506 -5.800 100.500 -7.350
201509 1.400 100.421 1.776
201512 -3.600 99.947 -4.588
201603 -0.800 101.054 -1.008
201606 -2.600 102.002 -3.246
201609 -3.000 101.765 -3.755
201612 1.000 101.449 1.255
201703 -5.230 102.634 -6.490
201706 2.320 103.029 2.868
201709 -1.400 103.345 -1.725
201712 -1.440 103.345 -1.775
201803 -0.830 105.004 -1.007
201806 -0.500 105.557 -0.603
201809 -0.390 105.636 -0.470
201812 -0.430 105.399 -0.520
201903 -0.540 106.979 -0.643
201906 -0.520 107.690 -0.615
201909 -0.070 107.611 -0.083
201912 -0.220 107.769 -0.260
202003 -0.450 107.927 -0.531
202006 -0.240 108.401 -0.282
202009 -0.170 108.164 -0.200
202012 -0.200 108.559 -0.235
202103 -0.360 110.298 -0.416
202106 -0.210 111.720 -0.239
202109 -0.200 112.905 -0.226
202112 -0.210 113.774 -0.235
202203 -0.250 117.646 -0.271
202206 -0.200 120.806 -0.211
202209 -0.140 120.648 -0.148
202212 -0.150 120.964 -0.158
202303 -0.160 122.702 -0.166
202306 -0.170 124.203 -0.174
202309 -0.120 125.230 -0.122
202312 -0.140 125.072 -0.143
202403 -0.200 126.258 -0.202
202406 -0.160 127.522 -0.160
202409 -0.140 127.285 -0.140
202412 -0.190 127.364 -0.190

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ESSA Pharma  (NAS:EPIX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


ESSA Pharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of ESSA Pharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ESSA Pharma Business Description

Traded in Other Exchanges
N/A
Address
999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.
Executives
Biotech Growth N V 10 percent owner ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Peter Virsik officer: Chief Operating Officer 131 ESCANYO WAY, PORTOLA VALLEY CA 94028
David Ross Parkinson director, officer: Chief Executive Officer C/O THRESHOLD PHARMACEUTICALS, INC., 170 HARBOR WAY SUITE 300, SOUTH SAN FRANCISCO CA 94080
Franklin M Berger director 1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Lauren Merendino director C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David S. Wood officer: Chief Financial Officer 3516 WEST 33RD AVE, VANCOUVER A1 V6N 2H4
Philip W. Kantoff director 3675 MARKET STREET, SUITE 200, PHILADELPHIA PA 19104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104

ESSA Pharma Headlines

From GuruFocus